HEALTHJul 10 · 13:35 UTCSTAT NEWSMeghana Keshavan and John Wilkerson

STAT+: Roche ends Huntington’s gene-silencing programs

Roche has discontinued two Huntington’s gene-silencing drugs due to disappointing data. ARPA-H announced a $160 million initiative to accelerate gene-editing therapies for rare diseases. Drugmakers are promoting Medicare’s new obesity drug discount program.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

RocheorganizationHuntington’s gene-silencingtopicARPA-Horganizationgene-editing therapiestopicMedicareorganizationobesity drug discount programtopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 4 · 13:17 UTC
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
HEALTHJun 24 · 11:55 UTC
STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval
HEALTHMay 26 · 13:28 UTC
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
HEALTHJun 3 · 13:17 UTC
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more